Research Peptide·Retatrutide UK
Retatrutide is a next-generation triple-agonist targeting the GLP-1, GIP and glucagon receptors. It currently shows the strongest weight-reduction signal in published phase-II obesity research, exceeding both semaglutide and tirzepatide in head-to-head arms.
HPLC Purity
Chain Shipped
UK Dispatch
The Research
Activates GLP-1, GIP and glucagon receptors simultaneously
Strongest published phase-II weight-loss data to date
Glucagon arm drives lipolysis and energy expenditure
Investigated for obesity, MASH and metabolic disease
Once-weekly dosing profile
Research context
Published phase-II data (Jastreboff et al., NEJM 2023) reported mean body-weight reductions up to ~24% at the 12mg dose over 48 weeks. Phase-III trials are ongoing. Retatrutide's triple-agonist mechanism is distinct from semaglutide (GLP-1 only) and tirzepatide (GLP-1 + GIP).
Typical Research Protocol
Drawn from published literature. Research context only, not medical advice.
Research Dose
1–12 mg per administration (research titration)
Frequency
Once weekly, subcutaneous
Duration
Research cycles commonly run 12–48 weeks with gradual titration
Common Stack
Typically studied as a monotherapy; not commonly stacked
FAQ
Cold-chain shipped from the UK. 24-hour dispatch. Discreet packaging every time.
View Product & Price